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Abstract: Over the last few decades, the prevalence of allergic diseases has increased 
dramatically in developed nations.  Mast cells (MCs) play a key role in allergic 
responses.  However, it is difficult to isolate high numbers of viable and mature MCs.  
Others have determined methods to grow MCs in traditional two-dimensional (2D) cell 
culture from various adult stem cell sources. Our previous studies have shown that it is 
possible to develop committed MC precursors in a 3D extracellular matrix-like 
environment.  Our long-term goal is to develop a tissue-engineered vascular model that 
includes CD133+ hematopoietic stem cells (HSCs) along with fibroblasts within a 3D 
matrix, to represent the tissue space, and a layer of endothelial cells (ECs) on one surface, 
to represent the capillary endothelium.  The objectives of this project were to identify 
which source of adult human CD133+ HSCs generated the greatest number of viable and 
mature MCs within the model and to determine the effect of fibroblasts and ECs to the 
growth and differentiation of MCs within the model.  HSCs from human adult peripheral 
blood mononuclear cells (PBMC), adult granulocyte colony-stimulating factor-mobilized 
peripheral blood mononuclear cells (G-PBMC), and cord blood were mixed with 
fibroblasts within a collagen matrix and incubated with StemSpan media supplemented 
with cytokines.  Samples were incubated for eight weeks, with ECs seeded on the surface 
of the matrix in the last week. MCs were characterized based on cell morphology, 
viability, intracellular stores of preformed factors, cell surface marker expression, and the 
release of soluble mediators.  The results show that HSCs isolated from G-PBMC 
generated the greatest number of viable and mature MCs within the 3D co-culture model.  
The data demonstrated that 3D co-culture system had a higher yield of mature MCs than 
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Over the last few decades, the prevalence of allergic diseases has increased dramatically 
in developed nations.  Allergic disease is the 5th leading chronic disease in the United 
States among all ages, and the 3rd most common chronic disease among children under 18 
years old [1].  A recent nationwide survey found that more than half of all U.S. citizens 
test positive to one or more allergens [2].  The cost associated with allergic diseases are 
more than 7 billion dollars per year [1].  Basic and clinical studies suggest that 
inflammation plays a role not only in obvious allergic responses, such as in asthma and 
eczema, but also ailments just recently associated with inflammation—such as 
atherosclerosis, Alzheimer's disease, colon cancer, and diabetes.  Therefore, the study of 
inflammation not only contributes to the study of allergic diseases, but also has much 
wider implications associated with the possible involvement of inflammation in the 
underlying mechanisms of other types of diseases, leading to possible clues to the 
prevention or treatment of these other diseases. 
Few tools are available currently to study allergic reactions and inflammation. Animal 
studies, clinical studies, and monolayers of cultured cells (2D cell culture) have 
contributed to our current understanding of allergy and have provided valuable 
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information toward our understanding of inflammatory mediators, cellular and tissue 
specific responses, and medical interventions.  The inherent limitation of animal models 
is that they do not generally translate to human responses, especially in the case of 
allergic responses [3-7].  The usefulness of human tests is limited by their empirical 
nature, dependence on trial and error approaches, and the possibility of severe 
complications [8-12].  Cell culture of various animal and human cells has been used to 
study allergic reactions in vitro [13, 14].  However, a 2D cell culture system cannot 
completely recapitulate the organized cellular structure of tissues in vivo. To approximate 
the in vivo microenvironment within an in vitro system, 3D models are more appropriate.  
The 3D tissue environment affects integrin ligation, cell contraction, and associated 
intracellular signaling [15, 16].  A 3D matrix is also important for solute diffusion and 
interaction with growth factors and enzymes resulting in tissue-scale solute concentration 
gradients and intercellular gradients.  Furthermore, a 3D environment is necessary to 
model morphogenetic and remodeling events that occur over larger-length scales, such as 
epithelial acinar formation [17, 18] and cluster formation in studies of T lymphocyte-cell 
behavior [19].  Our long-term goal is to develop 3D tissue-engineered skin and mucosal 
models that contains multiple human cell types within a 3D environment that provides for 
cell movement and interaction, in order to investigate some of the key aspects of an 
allergic inflammatory response.  In addition, to recapitulate an in vivo inflammatory 
response, the 3D tissue-engineered systems must contain the relevant cell types. 
Mast cells (MCs) are considered the central effector cells in the early events associated 
with allergic inflammatory responses [20-23].  Poised at the interface of the external 
environment in the skin and at mucosal surfaces, MCs are among the first cells to 
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encounter antigens that elicit allergic reactions [24].  The high-affinity immunoglobulin E 
(IgE) receptor on MCs, FcεRI, associates with IgE through its Fc region and forms a 
stable antigen receptor [15, 16, 25].  Upon binding multivalent allergen via this antigen 
receptor, MCs are activated and immediately release preformed mediator, such as 
histamine and neutral proteases like tryptase and chymase, present in their granules,.  
Activated MCs also synthesize and release other inflammatory mediators, such as 
prostaglandin D2 (PGD2), monocyte chemoattractant protein-1 (MCP-1), macrophage 
inflammatory protein-1 (MIP-1), tumor necrosis factor-alpha (TNF-α), granulocyte-
macrophage colony-stimulating factor (GM-CSF), interleukin-8 (IL-8), and IL-4 [26-31].  
Changes in the expression of adhesion molecules and costimulatory or inhibitory 
molecules occur with MC activation.  Collectively, these mediators initiate rapid vascular 
permeability and leukocyte recruitment [32-34]. 
Few studies have investigated normal, human MCs in culture.  There are considerable 
difficulties in isolating and analyzing MC populations directly ex vivo.  Unlike 
lymphocytes and monocytes, MCs do not circulate, but remain relatively fixed and 
dispersed in tissues under basal conditions.  Thus, there is no good repository of fully 
mature MCs from which to draw, in order to study their function ex vivo.  The secondary 
lymphoid organs normally contain resident MCs; however, even in inflammatory settings 
in which additional MCs migrate to the lymph nodes, the relative scarcity of cells, when 
compared with T cells or B cells, for example, prevents their use in any functional assays.  
Most early studies of MCs relied on the use of transformed MCs [35-38].  Although such 
cells have been instrumental in delineating MC signaling pathways and in revealing the 
wide variety of cytokines and chemokines that MC express, they are not useful for 
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assessing in vivo function.  The ability of MC differentiation factors, such as interleukin-
3 (IL-3) and stem cell factor (SCF), to act on CD133+/CD34+ progenitor cells isolated 
from peripheral blood, bone marrow, cord blood, or fetal liver have made it possible to 
grow large numbers of committed MC precursors [39-44].  These cells express high 
levels of the high-affinity IgE receptor FcεRI, contain preformed mediators that are 
present in MC granules, and express some of the inducible MC mediators associated with 
more mature tissue MCs [43]. 
The traditional 2D culture methods most commonly use a single cell type and grow cells 
on a culture dish or flask.  Many studies rely on the 2D method to generate MCs using 
peripheral blood, cord blood or bone marrow-derived progenitor cells.  For this study, the 
most common cell sources such as peripheral blood and cord blood were selected to 
generate MCs within a tissue-engineered vascular model [45-48].  The 2D cell culture 
method that was used in this study was selected based on previous studies [46, 49-51]. 
In order to create tissue-engineered models to study an allergic inflammatory response, 
we would need to be able to generate MCs from progenitor cells within the models, since 
it is difficult to obtain primary cells.  In a previous study, we have shown for the first 
time that it is possible to develop committed MC precursors in a 3D extracellular matrix-
like environment and that these cells are different than those generated from 2D cell 
culture systems [52]. For this project, we have developed a 3D tissue-engineered vascular 
model that includes CD133+ hematopoietic stem cells along with fibroblasts within a 3D 
matrix, to represent the tissue space, and a layer of endothelial cells (ECs) on one surface, 
to represent the blood endothelium.  Studies have shown that tissue fibroblasts and ECs 
contribute to the growth and differentiation of MCs, but the exact mechanisms are not 
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fully known [53, 54].  We hypothesize that the tissue-engineered vascular model can 
be used to develop MCs from stem cell sources and that the cells are more 
functional than those developed in 2D cell culture systems due to the influence of 
fibroblasts and ECs. To test our hypothesis as an initial step towards our long-term goal, 
it is necessary to complete the following project objectives:  
Objective 1:  Identify which source of human CD133+ hematopoietic stem cells 
generates the greatest number of viable and mature MCs within a 3D tissue-
engineered vascular model.  Based on the use of various cell sources in previous 
studies, we hypothesize that one source will result in the greatest number of viable and 
mature MCs within the 3D culture system.  
Objective 2: Determine the effect of fibroblasts and ECs on the growth and 
differentiation of MCs within the 3D tissue-engineered vascular model.  Unlike 
previous cell culture systems, the 3D culture system allows cells to interact with each 
other through direct contact and by soluble factors.  We will take advantage of this 
unique property to investigate the generation of MCs within the 3D tissue-engineered 
model compared to those in the 2D culture system. 
By meeting the project objectives, the following significant outcomes are possible: 1) the 
development of an advanced tissue culture system that can generate large numbers of 
viable and mature MCs to be used by researchers to study allergic responses, as well as 
the role of inflammation associated with many disease states; 2) new information about 
how stem cells develop within a 3D microenvironment; and 3) a better understanding of 












MATERIALS AND METHODS 
2.1. Antibodies and reagents 
StemSpanTM Serum-Free Expansion Medium (SFEM) cell culture medium was 
purchased from STEMCELL Technologies (Vancouver, Canada).  Human stem cell 
factor (SCF), interleukin (IL)-3, and IL-6 were obtained from PeproTech (Rocky Hill, 
NJ).  Defined HyClone fetal bovine serum (FBS) was from GE Healthcare Life Sciences 
(Logan, UT).  Zombie Green™ fixable viability kit, anti-human fluorochrome-conjugated 
CD117/c-kit (clone 104D2), FcεRI (clone CRA-1), CD31 (clone WM59), and the isotype 
controls, mouse IgG1 (clone MOPC-21), mouse IgG2b (clone MPC-11) were obtained 
from BioLegend (San Diego, CA).  Human myeloma IgE was from Athens Research & 
Technology (Athens, GA).  Goat anti-human IgE was acquired from Chemicon 
International (Temecula, CA).  
2.2. Isolation of human CD133+ cells 
2.2.1. Adult peripheral blood mononuclear cells (PBMCs) 
PBMCs were isolated from fresh leukocyte preparations (obtained from the Oklahoma 
Blood Institute; Oklahoma City, OK) by the Ficoll-Paque density separation method (GE 
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Healthcare). CD133+ cells were isolated from PBMCs using a magnetic separation kit 
(MACS Miltenyi Biotec; Auburn, CA), following the manufacturer’s protocol.   
2.2.2. Cord blood (CB)  
CD133+ cells from human cord blood were purchased from PromoCell (Heidelberg, 
Germany).  Hematopoietic progenitor expansion medium DXF and cytokine mix E, also 
from PromoCell, were used to expand the cells, following the manufacturer’s protocol.   
2.2.3. Granulocyte-colony-stimulating factor (G-CSF)-mobilized PBMCs  
CD133+ cells were obtained from G-CSF-mobilized PBMCs (obtained from Blood and 
Marrow Transplantation Program; University of Oklahoma, Oklahoma City, OK) by 
magnetic separation, as described previously.   
2.3. CD133+ Cell Culture 
CD133+ cells were cultured following a previously described protocol (Andersen, 2008). 
Briefly, the cells (50,000 cells/ml) were seeded in StemSpan medium supplemented with 
SCF (100 ng/ml), IL-6 (50 ng/ml), and IL-3 (1 ng/ml) (hitherto referred to as 
“supplemented media”) for the first three weeks with weekly media changes.  After three 
weeks, IL-3 was removed from the media.  One week prior to analysis, FBS (10%, v/v) 
was added to the media.  Samples were monitored weekly by contrast microscopy. 
2.4. Endothelial cell (EC) Culture 
Human umbilical vein endothelial cells (ECs) purchased from PromoCell were seeded in 
flasks coated with fibronectin (25 g/mL; Alfa Aesar, Tewksbury, MA). ECs were 
cultured in EC Growth Medium MV with supplement Mix (PromoCell) with media 
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changes every 72 h, until ECs reached >70% confluency.  The medium was replaced with 
StemSpan medium supplemented with 20% FBS for 24 h prior to use in the 3D tissue-
engineered vascular model. 
2.5. 3D tissue-engineered vascular model with fibroblasts and ECs 
Frozen FibroGROTM xeno-free mitomycin C treated human foreskin fibroblasts 
purchased from Millipore Sigma (Burlington, MA) were thawed and added to serum-free 
StemSpan medium, until ready for use.  A 2 mg/ml collagen solution was prepared, as 
described by Derakhshan et al., using 64.5 vol% of 3.1 mg/ml type 1 bovine collagen 
(Advanced BioMatrix, Carlsbad, CA), 8.1 vol% 10× M199, 13.3 vol% 0.1N NaOH, and 
14.1 vol% PBS.  The collagen solution was mixed with CD133+ progenitor cells (6.8 
×104 cells/ml) and fibroblasts (4.0 ×104 cells/ml) and added to 48-well cell culture plates.  
After 45 mins, the collagen-cell solution formed a gel and supplemented media was 
added to the samples, with media changes once a week.  After three weeks, IL-3 was 
removed from the media.  One week prior to analysis, samples were coated with a 
fibronectin solution (25 g/mL) and seeded with ECs (5.5 ×104 cells/cm2) in the 
StemSpan medium supplemented with 20% FBS.  
2.6. Characterization of CD133+-derived MCs  
2.6.1 Yield and granule formation 
The number of viable MCs and MC granule formation was studied using Wright-Giemsa 
to stain metachromatic cells [45]. To collect cells from the 3D tissue-engineered vascular 
model, the collagen matrix was digested by incubation with 2 mg/ml of collagenase D 
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(Roche Applied Science; Indianapolis, IN) for 1 h. The collected cells were counted 
using a hemocytometer and the number of viable cells was determined by Trypan blue 
exclusion method. Cytosolic granule formation was determined by Wright-Giemsa 
staining using an automated stainer (Ames Hema-Tek Stainer).  MC ratio was calculated 
as the ratio of the granular cells to the non-granular cells.  Cell yield was calculated as the 
ratio of the number of viable, granular cells harvested from the system to the number of 
cells seeded. 
2.6.2 Phenotypic marker expression 
Expression of c-kit and FcεRI was assessed by flow cytometry. After the culture period, 
the expression of FcεRI was stabilized by incubating the cells for 24 h with myeloma IgE 
(2 μg/ml). Cells were collected and stained using anti-c-kit, anti-FcεRI, or relevant 
isotype controls, and analyzed by flow cytometry. Viable cells were determined by 
staining with the Zombie Green™ fixable viability kit. 
For immunocytochemical staining of tryptase and chymase granules, cells were collected 
and fixed using a fixation/permeabilization solution kit (BD Biosciences; CA). After 
incubation with a blocking solution containing 10% goat serum (v/v%, Gibco; CA) for 1 
h, cells were incubated with primary antibodies against tryptase, chymase, or relevant 
isotype controls. Next, a secondary antibody was added and incubated for 30 min at room 
temperature. The cells were incubated for at least 1 h in the staining buffer containing 
0.2% bovine serum albumin (BSA), prior to staining with anti-c-kit antibody and analysis 




2.6.3 CD133+-derived MC activation 
After the culture period, function of the generated MCs was examined by cross-linking 
the FcεRI receptors by IgE and anti-IgE antibodies for cell activation [45].  Cells were 
sensitized with 15 μg/ml myeloma IgE (Athens Research & Technology; Athens, GA) in 
complete media for 24 h and rinsed three times prior to activation with 25 g/mL of anti-
IgE (Chemicon International Inc.; Temecula, CA) in Tyrode’s solution (Boston 
BioProducts; Ashland, MA) supplemented with SCF and IL-6 for 1 h.  For the 3D tissue-
engineered vascular model, cells were activated within the collagen matrix. 
2.6.4 Gene expression 
For gene expression in response to activation, cells were collected and total RNA was 
extracted using TRI Reagent (Molecular Research Center, Cincinnati, OH) following 
manufacturer’s protocol. UltraPure™ Glycogen (0.5 mL; ThermoFisher Scientific) was 
included as a carrier for nucleic acid precipitation in ethanol. After DNase I treatment, 1 
mg of total RNA was used to synthesize complementary DNA (cDNA) using a cDNA 
synthesis kit (Thermo Fisher Scientific). Real-time PCR was performed using an ABI 
7500 fast Real-time PCR System (Applied Biosystems, Foster City, CA) and a reaction 
mixture qPCR MasterMix Plus (SYBR Green 2 ꞏ PCR Master Mix, a cDNA template, 
and forward and reverse primers). Primer sequences were as follows: (beta-actin-FW: 
GCCGGGACCTGACTGACTAC; beta-actin-RE: TTCTCCTTAATGTCACGCACGAT; 
PGD2-FW: GGCGTTGTCCATGTGCAAG; PGD2-RE: 
GGACTCCGGTAGCTGTAGGA; MCP-1 (CCL2)-FW: 
CAGCCAGATGCAATCAATGCC; MCP-1 (CCL2)-RE: 
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TGGAATCCTGAACCCACTTCT; IL-8-FW: ACTGAGAGTGATTGAGAGTGGAC; 
IL-8-RE: AACCCTCTGCACCCAGTTTTC; MIP-1α-FW: 
AGTTCTCTGCATCACTTGCTG; MIP-1α-RE: CGGCTTCGCTTGGTTAGGAA; 
TNF--FW: CCTGCTGCACTTTGGAGTGAT; TNF--RE: 
CAACATGGGCTACAGGCTTGT; IL-4-FW: GCAGCTGATCCGATTCCTGA; IL-4-
RE: TCCAACGTACTCTGGTTGGC; GM-CSF-FW: 
TCCTGAACCTGAGTAGAGACAC; GM-CSF-RE: TGCTGCTTGTAGTGGCTGG). 
Primers were synthesized by Sigma-Aldrich. Relative expression levels of PGD2, MCP-
1, IL-8, MIP-1, TNF-, IL-4, and GM-CSF were normalized to that of b-actin 
(housekeeping gene) expression using the 2-DDCT method [55].  
2.6.5 Histamine content and release 
For measuring histamine release, culture media without cells was collected.  For 
measuring the histamine content in the generated MCs, cells were collected and lysed by 
freeze-thaw cycles in water and sonication for 5 min [56].  Histamine was quantified 
using a histamine-specific ELISA (RefLab ApS; Copenhagen, Denmark) following the 
manufacturer’s protocol. The percentage of total histamine release was determined by the 
amount of histamine released by the cells in the culture media compared to the total 
histamine content, which included the extracellular histamine release and the intracellular 
histamine content. 
2.7 Statistical analysis 
Experimental results are expressed as the mean ± standard deviation of triplicate samples. 
For testing multiple groups, analysis of variance was used to determine whether there is a 
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significant difference between any of the groups (p-value < 0.05). Differences between 
two groups were determined using Student’s t-test, with a p-value < 0.5 considered 
significant. Statistical analyses were done using GraphPad Prism (GraphPad Software, 













3.1. Identifying which source of adult human CD133+ hematopoietic stem cells generates 
the greatest number of viable and mature MCs within a 3D tissue-engineered vascular 
model. 
3.1.1. Cell density  
Cell density increased for peripheral blood (PB)-, cord blood (CB)- and granulocyte 
colony-stimulating factor-mobilized peripheral blood mononuclear cell (G-PBMC)-
derived cells after eight weeks of culture in the 3D tissue-engineered vascular model, as 
shown in Fig. 1.  The microscopy images showed the cell concentrations increasing with 
the time in culture.  For each time point examined, there was no significant difference in 
cell density among the samples. 
3.1.2. Morphology 
Cell morphology was examined at Weeks 2, 4 and 8 by metachromatic staining using 
Wright-Giemsa and examined by contrast microscopy (Fig. 2). 
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The average size of the cells generated from CD133+ hematopoietic stem cells (HSCs) 
from PB was estimated to be 46.07 ± 9.96 μm, CB was estimated to be 35.17 ± 7.98 μm 
and G-PBMC was estimated to be 21.49 ± 3.34 μm after eight weeks of culture.  The 
cells generated from CD133+ HSCs from three different sources grown in the 3D tissue-
engineered vascular model with fibroblasts and ECs showed signs of maturity with 
secretory granules stained blue or violet (Fig.2). 
Figure 1.  Increasing cell density for peripheral blood (PB)-, cord blood (CB)- and 
granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells (G-
PBMC)-derived cells over eight weeks in a 3D tissue-engineered vascular model with 
fibroblasts and endothelial cells.  Samples were examined by phase contrast microscopy once 
a week.  Representative images are shown for triplicate samples of each group.  White arrows 
point to typical mast cells (MCs).  Black arrows point to typical fibroblasts.  J-L) Endothelial 




3.1.3. Proliferation / Relative cell yield 
The cells generated from G-PBMC-derived CD133+ HSCs showed a high number of 
granular cells and significantly greater cell yield compared with other cell sources. Cells 
generated from CB-derived CD133+ HSCs had the lowest number of granular cells and 
relative cell yield compared with the other two cell sources.   
3.1.4.  Expression of FcεRI in c-kit+ population 
The cells generated from PB-derived CD133+ HSCs that showed c-kit+/FcεRI+ expression 
increased from 19.06 ± 0.05% to 98.19 ± 1.43% after eight weeks of culture.  The cells 
Figure 2.  Morphological changes of peripheral blood (PB)-, cord blood (CB)- and 
granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells (G-
PBMC)-derived cells over eight weeks in a 3D tissue-engineered vascular model with 
fibroblasts and endothelial cells.  Cells were stained with Wright-Giemsa and examined by 
light microscopy.  Representative images are shown for triplicate samples of each group.  The 
granules of mast cells (MCs) stain a deep blue to violet.  Data are represented as mean ±SD; 




generated from CB-derived CD133+ HSCs that showed c-kit+/FcεRI+ expression 
decreased from 71.02 ± 1.37% to 12.45 ± 0.23%.  G-PBMC-derived progenitor cells with 
c-kit+/FcεRI+ expression increased from 18.64 ± 1.41% to 91.97 ± 0.34% after eight 
weeks of culture in the 3D tissue-engineered vascular model.  Cells were analyzed using 
Figure 3.  A) Ratio of granular mast cells (MCs) compared with non-granular cells for 
peripheral blood (PB)-, cord blood (CB)- and granulocyte colony-stimulating factor-mobilized 
peripheral blood mononuclear cells (G-PBMC)-derived cells in a 3D tissue-engineered 
vascular model with fibroblasts and endothelial cells. B) Relative cell yield for the number of 
granular MCs compared to the number of initial CD133+ cells from all three cell sources that 
were seeded in the 3D tissue-engineered vascular tissue model.  Data are represented as mean 





flow cytometry after two, four and eight weeks.  The gating strategy and representative 




Next, the c-kit+ population was gated and compared with isotype.  The expression of 
FcεRI in the c-kit+ population was then measured using histograms (Fig. 4B). 
3.1.5. Expression of tryptase and chymase 
The expression of tryptase and chymase by MCs derived from all three sources was 
measured by flow cytometry after two, four and eight weeks (Fig. 5A). The gating 
strategy is shown in Fig. 5A.  MCs were selected based on the cell size and granularity as 
forward scatter (FSC) and side scatter (SSC) parameters.  The MCs generated from 
CD133+ HSCs derived from all three sources displayed high levels of tryptase expression 
(>80%) after eight weeks of culture in the 3D culture system (Fig. 5B).  As shown in Fig. 
Figure 4.  Expression of  c-kit+/FcεRI+  cells derived from peripheral blood (PB)-, cord blood 
(CB)- and granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells 
(G-PBMC)-derived CD133+ progenitor cells during eight weeks of culture in a 3D tissue-
engineered vascular model with fibroblasts and endothelial cells.  A)  The gating scheme and 
representative density plots of the expression of phenotypic markers.  B)  Percentage of c-













Figure 5.  Expression of tryptase and chymase in cells differentiated from peripheral blood 
(PB)-, cord blood (CB)- and granulocyte colony-stimulating factor-mobilized peripheral blood 
mononuclear cells (G-PBMC)-derived CD133+ progenitor cells after eight weeks in a 3D tissue-
engineered vascular model with fibroblast and endothelial cells.  A)  The gating strategy to 
identify tryptase and chymase population; percentage of B) tryptase and C) chymase expression. 
Data are represented as mean ± SD; n=3.  * indicates p < 0.05. 
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3.1.6. Histamine content and histamine release 
The release of histamine was examined to determine the functionality of MCs.  In the 3D 
culture system, MCs generated from G-PBMC-derived CD133+ HSCs showed the highest 
histamine content compared with cells generated from PB- and CB-derived HSCs.  As 
shown in Fig. 6A, MCs generated from G-PBMC-derived CD133+ HSCs showed 40-fold 
histamine release after IgE activation compared with controls.  The histamine release 
after IgE activation was different among the cells generated from CD133+ HSCs for all 
three cell sources.  Fig. 6B shows the histamine content at Weeks 2, 4 and 8 with three 
different cell sources cultured in 3D.  The data demonstrates that the histamine levels 
were below 1 pg/cell at Weeks 2 and 4 for the cells generated from CD133+ HSCs all 
three cell sources.  However, after eight weeks of culture, histamine levels increased 
significantly especially for the MCs generated from PB- and G-PBMC-derived CD133+ 
HSCs. 
3.1.7. Expression of cytokine and chemokine genes 
 RT-PCR was used to determine the expression of key chemokines and cytokines of the 
cells cultured in the tissue-engineered vascular model with fibroblast and ECs and the 
results are shown in Fig. 7. 
Overall, the majority of the cytokine genes showed upregulation at Week 8 for MCs 
derived from all three cell sources.  PGD2 showed no upregulation until Week 8 for MCs 
generated from PB- and CB-derived CD133+ HSCs.  MCP-1, GM-CSF and IL-8 were 
upregulated for MCs generated from all three cell sources at Week 2, 4 and 8.  MIP-1 
was upregulated for MCs generated from derived from all three sources except MCs 
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generated from PB- and CB-derived CD133+ HSCs at Weeks 4 and 8, respectively.  TNF-
α was upregulated in MCs derived from PB and G-CSF and IL-8 were upregulated for 
Figure 6.  Histamine content and release from peripheral blood (PB)-, cord blood (CB)- and 
granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells (G-PBMC)-
derived cells in a 3D tissue-engineered vascular model with fibroblasts and endothelial cells.  A) 
Histamine content was measured after two, four and eight weeks of culturing without IgE 
activation.  B) Histamine release after immunoglobulin E (IgE) activation was measured after 





MCs generated from all three cell sources at Week 2, 4 and 8. MIP-1 was upregulated for 
Figure 7.  Fold increase in cytokine and chemokine genes in activated cells compared to and 
control cells from; human peripheral blood (PB)-, cord blood (CB)- and granulocyte colony-
stimulating factor-mobilized peripheral blood mononuclear cells (G-PBMC)-derived CD133+ 
cells in a 3D tissue-engineered vascular model with fibroblasts and endothelial cells.  
Activated cells were sensitized for 24h by the addition of monomeric immunoglobulin E (IgE) 
followed by crosslinking with anti-IgE receptors for 1h. Data are represented as mean ± SD; 





MCs generated from all three sources except MCs generated from PB- and CB-derived 
CD133+ HSCs at Weeks 4 and 8, respectively.  
TNF-α was upregulated in MCs derived from PB and G- PBMC sources at Week 8. IL-4 
expression was the highest in MCs generated from PB- and CB-derived CD133+ HSCs at 
Week 2 but decreased afterward.  
3.2. Determining the effect of fibroblasts and ECs on the growth and differentiation of 
MCs within the 3D tissue-engineered vascular model by comparing the generation of 
MCs from the 3D tissue-engineered vascular model to MCs from the 2D culture system 
3.2.1. Cell density 
Cell density increased in MCs generated from CD133+ HSCs derived from three sources 
after 8 weeks of culture in the 3D tissue-engineered vascular model as well as 2D cell 
culture system (Fig. 8).  The cell density increased from Week 2 and the cells from 3D 
and 2D cell culture systems started to form colonies.  In both systems, the cell density 
increased with culture time.   
3.2.2. Cell morphology 
Morphological changes in cells derived from three sources in the 3D co-culture system 
and 2D cell culture system at Week 2, 4 and 8 were observed by metachromatic staining 
(Fig. 9).  Mature MCs contained cytoplasmic granules that stained metachromatically 
with Wright-Giemsa.  MCs derived from 3D and 2D cell culture models showed maturity 



















































































































































































































































































































Figure 9.  Morphological changes of peripheral blood (PB)-, cord blood (CB)- and 
granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells (G-
PBMC)-derived cells over eight weeks in a 2D model without fibroblasts and endothelial 
cells (ECs) and 3D culture system with fibroblasts and ECs. A) Cells were stained with 
Wright-Giemsa and examined by light microscopy.  Representative images are shown for 
triplicate samples of each group.  The granules of MCs stain a deep blue to violet.  B)  
The average size of mast cells (MCs) after eight weeks of culture. Data are represented as 





The average MC sizes were very similar between the cell culture systems for three 
different cell sources.  The cells generated from PB and CB were comparable.  The 
average cell sizes for cells generated from G-PBMC were the smallest for both 2D and 
3D culture systems.   
A key difference between the two culture systems was that the 3D co-culture system 
showed a higher relative cell yield compared to the 2D system, especially for G-PBMC-
derived CD133+ HSCs.  However, there was no significant difference in CB-derived cells 
between the two culture systems.  In both 2D and 3D systems, PB- and G-PBMC-derived 
cells had the highest relative cell yield at Week 4, but decreased by Week 8. 
3.2.3. Expression of FcεRI in c-kit+ population 
Cells that were cultured in the 3D co-culture system had a higher expression of FcεRI in 
the c-kit+ population than the 2D model (Figs. 11).  The FcεRI expression for c-kit+ cells 
generated from CB-derived CD133+ HSCs at Week 4 and Week 8 was comparable 
between the two culture systems.  In contrast, the c-kit+ cells generated from PB- and G-
PBMC-derived CD133+ HSCs had a higher expression of FcεRI in the 3D culture, when 
compared to 2D cultures at Weeks 2 and 4.  This data indicated that the 3D tissue-
engineered vascular model with fibroblasts and ECs were able to generate MCs with 
FcεRI expression in c-kit+ population. 
3.2.4. Expression of tryptase and chymase 
MCs generated from PB- and G-PBMC-derived CD133+ HSCs showed a high expression 
(>90%) of tryptase and chymase in both 2D and 3D culture systems (Figs. 12B, C). 
Interestingly, in 2D cultures, the tryptase expression increased over time in MCs 
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Figure 10. Relative cell yield from peripheral blood (PB)-, cord blood (CB)- and granulocyte 
colony-stimulating factor-mobilized peripheral blood mononuclear cells (G-PBMC)-derived 
CD133+ progenitor cells during eight weeks of culture in a 2D model without fibroblasts and 
endothelial (ECs) and a 3D culture model with fibroblasts and ECs.   Data are represented as 








Figure 11.  Expression ofc-kit+/ FcεRI+ from peripheral blood (PB)-, cord blood (CB)- and 
granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells (G-
PBMC)-derived CD133+ progenitor cells during eight weeks of culture.  A)  The gating 
scheme and representative density plots of the expression of phenotypic markers using flow 
cytometry.  B)  The bar graphs show the percentage of c-kit+/ FcεRI+expression.  Data are 






generated from PB-derived HSCs (Figs. 12). However, in the 3D cultures, tryptase 
expression by these cells increased after an initial decrease. The cells generated from CB-
derived CD133+ HSCs had higher tryptase expression at Week 8 in the 3D co-culture  
system compared to the 2D system.  The expression of chymase in cells generated from 
PB- and G-PBMC-derived CD133+ HSCs steadily increased in 2D cell culture system. 
Our results showed that both the 3D and 2D systems could generate mature MCs.  
However, only the 3D system could generate MCs with >80% tryptase expression from 
all three sources. 
3.2.5. Histamine content and release 
The cells generated from PB-, CB- and G-PBMC-derived CD133+ HSCs produced 
histamine in both 2D and 3D culture systems (Figs. 12).  The CD133+ HSCs generated 
from the 3D culture model displayed a measurable histamine content.  For histamine 
release and histamine content, cells generated from PB and CB at the 2D system had a 
higher histamine release level than the 3D culture mode.  The cells generated from G-
PBMC had a higher histamine content and release level when cultured in the 3D culture 
system than in 2D culture system.  
3.2.6. Expression of cytokine and chemokine genes  
To determine if the soluble factors from the fibroblasts and ECs within the 3D culture 
system contribute to MC growth and differentiation, the levels of the cytokines and 
chemokines from the 2D and 3D systems were measured (Fig. 14).  Histamine was 
measured for the cells generated from the G-PBMC at Week 2 and 4 but the values were 
33 
 
below the range of the analysis.  In the 2D culture system, more cytokine genes were 
upregulated compared to the 3D co-culture system with fibroblasts and ECs (Fig. 14). All 
the cytokine genes showed upregulation for cells generated from PB and CB in the 2D 














Figure 12.  Expression of tryptase and chymase in cells differentiated from peripheral blood 
(PB)-, cord blood (CB)- and granulocyte colony-stimulating factor-mobilized peripheral blood 
mononuclear cells (G-PBMC)-derived CD133+ progenitor cells after eight weeks in a 3D co-
culture system and 2D culture system without fibroblasts and ECs.  A)  The gating strategy to 
identify tryptase and chymase population; percentage of B) tryptase and C) chymase expression. 
Data are represented as mean ± SD; n=3. * indicates p < 0.05.  Data are represented as mean 









Figure 13.  Histamine content and release from peripheral blood (PB)-, cord blood (CB)- and 
granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells (G-PBMC)-
derived cells in a 2D cell culture model without fibroblasts and endothelial cells (ECs) and a 3D 
tissue-engineered vascular model with fibroblasts and ECs.  A) Histamine was measured after 
two, four and eight weeks of culturing without immunoglobulin E (IgE) activation.  B) Histamine 
release was measured after eight weeks of culture.  Data are represented as mean ±SD; n=3.  * 














Figure 14.  Fold increase in cytokine and chemokine genes in activated and control cell 
differentiated from human A) peripheral blood (PB)-,  B) cord blood (CB)- and C) granulocyte 
colony-stimulating factor-mobilized peripheral blood mononuclear cells (G-PBMC)-derived 
CD133+ cells in a 2D cell culture system without fibroblasts and endothelial cells (ECs) and a 3D 
tissue-engineered vascular model with fibroblasts and ECs.  Activated cells were sensitized for 
24h by the addition of monomeric immunoglobulin E (IgE) followed by crosslinking with anti-















4.1. Identifying which source of adult human CD133+ hematopoietic stem cells generates 
the greatest number of viable and mature MCs within a 3D tissue-engineered vascular 
model. 
4.1.1. Cell proliferation and morphology  
The cells generated from peripheral blood (PB)-, cord blood (CB)- and granulocyte 
colony-stimulating factor-mobilized peripheral blood mononuclear cell (G-PBMC) 
started to form colonies, which is a key characteristic for MCs [57].  Microscopy images 
showed the cell concentrations increasing with culture period (Fig. 1).  It was difficult to 
differentiate the proliferation and cell numbers between three cell sources solely based on 
phase contrast microscopy images.  Hence Wright-Giemsa stain was used to determine 
the cell proliferation and cell numbers (Fig. 2). 
Studies have shown that MCs are round in shape, while fibroblasts are elongated when 
co-cultured in collagen [58].  ECs are cobblestone in appearance, and sometimes form 
incomplete loops when co-cultured with MCs [59].  MCs are 10-20 μm in size and have 
round nuclei but studies have suggested with continued growth of granules, MCs can 
reach 20-30 μm in diameter [60-62].  A key feature of MCs are the granules which stain 
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purple and violet following metachromatic staining [63, 64].  Approximately 50% of the 
cytoplasm of mature MCs are filled with granules [65].  MC differentiation is involved in 
different pathological and physiological processes through direct cell-cell interactions or 
the release of mediators [66].  Studies have shown that when MCs are cultured in loose 
connective tissue environment, MCs are more likely to become round in shape, however, 
when MCs are cultured in close contact with blood vessels, MCs appear ovoid or 
elongated.  Furthermore, when MCs are cultured in dermal fibers, they become spindle-
shaped or threadlike.  It is usual for MCs to have more than one nucleus [62].  The cells 
generated from CD133+ HSCs from three different sources grown in the 3D tissue-
engineered vascular model with fibroblasts and ECs showed signs of maturity with 
secretory granules stained blue or violet (Fig. 2).   
The cells generated from G-PBMC-derived CD133+ HSCs showed an average of 1.5-fold 
cell yield compared with other cell sources.  As shown in Figs. 1 – 3, phase contrast 
microscopy and Wright-Giemsa images support the relative cell yield calculation.  G-
PBMC-derived progenitor cells had the highest relative cell yield compared with cells 
generated from PB- and CB-derived CD133+ HSCs in 3D tissue-engineered vascular 
model with fibroblasts and ECs. 
Researchers have shown G-PBMC had a significant reduction in the proportion of 
apoptotic cells in the progenitor cells population compared to unstimulated PB-derived 
progenitor cells [67-70].  This might explain the high relative cell yield and MCs ratio 
from cells generated from G-PBMC but firm conclusions on the exact effect on 
granulocyte colony-stimulating factor (G-SCF) remains to be established. 
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4.1.2.  Expression of FcεRI in c-kit+ population 
FcεRI is a high-affinity IgE receptor, essential for the induction of IgE-mediated allergic 
reactions.  Cross-linking of cell surface FcεRI begin with IgE binding with antigens.  
This is followed by MC degranulation and the release of different inflammatory 
mediators that provoke allergic inflammation.  However, many studies have shown that 
MCs lack FcεRI both in vivo and in vitro conditions [45, 71].  Researchers have shown 
that almost two-thirds of MCs cultured from normal human dermis expressed faint to no 
FcεRI using dual-color immunohistochemical staining [72].  Other studies have reported 
FcεRI expression had a range of 30-40% in PB- and CB-generated cells [45]. Taken 
together, the data indicate that CB-derived HSCs was not a suitable source for generating 
c-kit+/FcRI+ MCs.  
A major difference between PB/G-PBMC and CB is their abilities in the number and type 
of differentiated cell types they can differentiate.  CB stem cells are pluripotent and can 
become all cell types.  PB stem cells are limited to differentiating into different cell types. 
4.1.3. Expression of MCs mediators 
When a specific allergen, cytokines, or immunoglobulin E (IgE) triggers MCs through 
high-affinity surface IgE receptors and FcεRI cross-linking, this causes MC activation 
and release of a range of rapid inflammation mediators from MC granules, such as 
histamine, neutral proteases like tryptase and chymase, cytokines, chemokines and many 
proteases that rapidly interact with connective tissue, vasculature and inflammatory cells 
within minutes [73].  The two MC subtypes that have been discovered in tissue include 
the MCs where the granules contain only protease tryptase (MCT) or where the granules 
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contain both tryptase and chymase (MCTC).  The cells generated from three cell sources 
had over 80% tryptase expression. 
The histamine content and release were examined to determine the functionality of MCs.  
In the 3D culture system, the cells generated from G-PBMC-derived CD133+ HSCs 
showed the highest histamine content compared with cells generated from PB- and CB-
derived HSCs.  This might relate to G-CSF stimulates the development of MCs 
progenitor cells [70, 74]. 
IgE activation cause MCs to produce a range of pro-inflammatory mediators including 
multiple cytokines and chemokines [75, 76].  Of these, PGD2, MCP-1, IL-8, MIP-1, 
TNF-α, IL-4 and GM-CSF are of pathological significance for mature MCs [77].  When 
an IgE triggers MCs through high-affinity surface IgE receptors and FcεRI cross-linking, 
MCs are activated and release a range of rapid inflammation mediators, such as 
cytokines, chemokines and many proteases that rapidly interact with connective tissue, 
vasculature and inflammatory cells [73].  These mediators have an intense effect on 
surrounding tissues and can cause a broad range of cellular responses, including 
tumorigenesis [78].  The molecular mechanisms and relationship between MCs and co-
stimulatory molecules remain unclear.  TNF-α is a common cell signaling protein that 
included in different pathological states and it is important to study its impact on MCs in 
regulating immune responses [79, 80].  Mature MC is known for its expression of GM-
CSF receptors [81].  MCP-1 and IL-8 are common chemokines and their productions can 




MCs cytokine expression and production are needed to fully understand the exact 
mechanisms. 
4.2. Determining the effect of fibroblasts and ECs on the growth and differentiation of 
MCs within the 3D tissue-engineered vascular model by comparing the generation of 
MCs from the 3D tissue-engineered vascular model to MCs from the 2D culture system 
4.2.1. Cell proliferation and morphology  
The comparison of cell density from cells generated from PB, CB and G-PBMC were 
cultured in 3D tissue-engineered vascular model and 2D traditional cell culture system 
shown the microscopy images were indistinguishable.  Fig. 8 shown cells were started to 
form colonies at Week 2, which is a key characteristic for MCs. 
Wright-Giemsa were used to stain the cells and investigated the morphology of the cells 
that were cultured in the two cell culture systems.  The generated cells from both cell 
culture systems shown signs of maturity with secretory granules stained blue or violet 
(Fig.9).   
The cells generated from PB and G-PBMC had a higher relative cell yield than CB.  It 
might indicate the adult stem cell type are different than CB-derived progenitor cells. 
Regardless, results from the morphology and cell proliferation experiments demonstrated 
that the 3D co-culture systems had the ability to differentiate MCs from CD133+ 





4.2.2.  Expression of FcεRI in c-kit+ population 
The cells generated from the 3D co-culture system had a higher FcεRI expression 
compared to the 2D cell culture system.  This result indicated the possibility of fibroblast 
and ECs stimulating the growth of MCs from HSC in the 3D tissue-engineered vascular 
model. 
4.2.3. Expression of MC mediators 
The cells cultured in both 2D and 3D cell culture systems from three cell sources shown 
tryptase and chymase expression.  It is possible that for the tryptase and chymase 
expressions, fibroblasts and ECs has a limited effect on the progenitor cells differentiated 
MCs.  
The cells cultured in both 2D and 3D cell culture systems from three cell sources showed 
detectable histamine content and release when activated.  In order to trigger 3D cultured 
MCs through IgE receptors and FcεRI cross-linking, IgE and anti-IgE were added 
directly on top of the collagen gel. This could cause the release of histamine; however, 
the released histamine might get trapped in the collagen gel.  As the IgE and anti-IgE 
were not directly in contact with the cells in the 3D culture system, it could affect the 
histamine levels. It might also explain the higher levels of histamine in PB- and CB-
generated cells in the 2D culture system. 
The cells cultured in the 3D and 2D culture systems showed upregulated expression of 














Allergic diseases have increased dramatically in many nations and mast cells are key 
effector cells in the allergic inflammatory response.  MCs do not circulate but remain 
relatively fixed and dispersed in tissues and it is difficult to isolate high numbers of 
viable and mature cells.  Due to the traditional 2D environment cannot completely 
recapitulate the organized cellular structure of tissues in vivo, it is important to develop 
an in vivo microenvironment that mimics the human tissue layer.   
PB-, CB- and G-PBMC-derived progenitor cells were cultured in a 3D tissue-engineered 
vascular model with FCs and ECs for eight weeks to determine which sources provided 
the highest number of viable and mature MCs.  After comparing the morphology, 
proliferation, FcεRI in the c-kit+ population, tryptase and chymase expression, histamine 
levels, and cytokine and chemokine expression,  It was determined that G-PBMC-derived 
progenitor cells generate the greatest number of viable and mature MCs within a 3D 
tissue-engineered vascular model based on the result showed that G-PBMC had the 
highest proliferation rate and tryptase and chymase expression, a high FcεRI expression 
in the c-kit+ population and histamine level. 
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Comparing to cells grown in the 2D system without FCs and ECs, the 3D tissue-
engineered vascular model with FCs and ECs generated a greater number of mature MCs 
based on the result showed that 3D cell culture system had the highest proliferation rate 
and FcεRI expression in the c-kit+ population, high level of tryptase and chymase 
expression and histamine level. This result suggests that fibroblasts and ECs may 
contribute to the growth and differentiation of MCs.  Even though the 3D co-culture 
system generated a greater number of viable and mature MCs, we believe that the system 
still needs to be optimized.  The protocol for this new culture system was based on a 
protocol for standard 2D cell culture. Therefore, the distinct differences between the two 
systems, such as a co-culture within a 3D matrix, should be taken into account to 
optimize the 3D system. 
In conclusion, these results indicate that the tissue-engineered vascular model can be used 
to develop MCs from various stem cell sources and that the cells may be more functional 
than those developed in 2D cell culture systems, due to the influence of fibroblasts and 
ECs.  These results highlight the possibility of using the tissue-engineered vascular model 
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